The U.S. Food and Drug Administration on Monday granted accelerated approval to Pfizer's therapy for treating patients with a type of blood cancer that is difficult to treat, the company said.
A compagny logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Phototherapy for treating patients with a type of blood cancer that is difficult to treat, the company said.
The health regulator's decision allows use of the therapy, branded as Elrexfio, in patients with multiple myeloma that is hard to treat or has come back after receiving four or more prior lines of certain classes of treatments. Elrexfio, or elranatamab, is administered under the skin and belongs to a class of therapies known as bispecific antibodies, that helps the body's immune system to kill cancerous cells by bringing a cancer cell and an immune cell together.Multiple myeloma is a common type of blood cancer, which develops in the bone marrow and can spread throughout the body. Several patients see a relapse after stopping treatment, making it an area of unmet need that drugmakers can tap into.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Listeria outbreak may be linked to recalled ice cream cups, FDA saysTwo people have recently been hospitalized from the bacteria, according to officials.
Read more »
Do not use certain pregnancy, ovulation, UTI tests, FDA warns | CNNConsumers shouldn’t use certain tests manufactured by Universal Meditech Inc., the US Food and Drug Administration warned Friday, including those that test for pregnancy, ovulation and urinary tract infections.
Read more »
Pregnancy, ovulation and urinary tract infection tests are being recalled. Here's what you need to know.The Food and Drug Administration (FDA) is urging consumers to avoid certain consumer testing products. Here's a list.
Read more »
FDA: Avoid using Universal Meditech pregnancy, ovulation testsRECALL ALERT: A variety of products that test for pregnancy, ovulation, urinary tract infections and more, are being recalled. recall
Read more »
Revance's Botox rival gets FDA approval for painful neck muscle conditionThe U.S. health regulator has approved expanding the use of Revance Therapeutics' Daxxify to treat a painful neck muscle condition, intensifying the anti-wrinkle injection's rivalry with AbbVie's Botox.
Read more »